San Francisco-based Imago BioSciences Inc., a clinical-stage biotechnology company, has raised $40 million in Series B financing round.
The round was led by Omega Funds with participation from existing backers including Frazier Healthcare Partners, Amgen Ventures, and MRL Ventures Fund as well as HighLight Capital, Pharmaron and Greenspring Associates.
Imago BioSciences plans to use the funds to accelerate the research and clinical development program of therapeutics for myelofibrosis and other myeloid neoplasms.
To date, the company has nabbed a total of $66.5 million in over two funding rounds.